Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
- Patient Reported Outcomes (PROs) should be part of all drug development from the earliest trials to what’s on the label. At ASH 2018, Dr. Nabhan and Dr. Koffman talk about how we are falling short.
- This is really important: patients are getting the wrong care and not only is it not helping and often hurting them, it even costs more. See Dr. Koffman’s interview with Dr. Nabhan.
- Acalabrutinib, a potent targeted oral therapy moved one step closer to approval for CLL with the FDA’s granting Breakthrough Therapy Designation on Aug. 14, 2019. Read more along with a link to the press release.
- It is only by understanding how CLL cells grow and resist treatment that we can develop successful therapies. Dr. Kay has done basic science research on the bone marrow stromal support of CLL and in doing so has learned a novel approach that might be able to improve treatment and it’s already in a clinical trial. Watch the interview.